This case illustrates that co-administration of anti-PD-1 with anti-IL-6R in patients with advanced melanoma and Crohn’s disease can be well tolerated and may attenuate or delay autoimmune exacerbation without impacting a positive anti-tumor effects. Here, PDCD1 is linked to melanoma.